Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (TOI) EBITDA Margin (2021 - 2025)

Historic EBITDA Margin for Oncology Institute (TOI) over the last 5 years, with Q3 2025 value amounting to 5.16%.

  • Oncology Institute's EBITDA Margin rose 79000.0% to 5.16% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.05%, marking a year-over-year increase of 78900.0%. This contributed to the annual value of 14.47% for FY2024, which is 84000.0% up from last year.
  • As of Q3 2025, Oncology Institute's EBITDA Margin stood at 5.16%, which was up 79000.0% from 8.5% recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's EBITDA Margin ranged from a high of 1.89% in Q2 2021 and a low of 77.56% during Q4 2021
  • Moreover, its 5-year median value for EBITDA Margin was 15.86% (2023), whereas its average is 20.36%.
  • Over the last 5 years, Oncology Institute's EBITDA Margin had its largest YoY gain of 431000bps in 2022, and its largest YoY loss of -296500bps in 2022.
  • Quarter analysis of 5 years shows Oncology Institute's EBITDA Margin stood at 77.56% in 2021, then soared by 56bps to 34.47% in 2022, then soared by 51bps to 16.88% in 2023, then surged by 35bps to 10.97% in 2024, then skyrocketed by 53bps to 5.16% in 2025.
  • Its EBITDA Margin stands at 5.16% for Q3 2025, versus 8.5% for Q2 2025 and 8.52% for Q1 2025.